BioCryst Pharmaceuticals, Inc.
General ticker "BCRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.8B (TTM average)
BioCryst Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 37.1%.
Estimated limits based on current volatility of 1.5%: low 9.71$, high 10.01$
Factors to consider:
- Total employees count: 580 (+8.2%) as of 2024
- US accounted for 85.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Sustained profitability, Clinical trial failure, Regulatory and compliance, Manufacturing disruptions, Market competition
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.24$, 10.56$]
- 2026-12-31 to 2027-12-31 estimated range: [5.61$, 11.12$]
Financial Metrics affecting the BCRX estimates:
- Positive: with PPE of 6.4 at the end of fiscal year the price was low
- Positive: Operating cash flow per share per price, % of 21.60 > 13.08
- Positive: Operating profit margin, % of 38.98 > 18.77
- Negative: negative Industry operating cash flow (median)
- Negative: Interest expense per share per price, % of 4.90 > 3.34
- Negative: Shareholder equity ratio, % of -23.17 <= 18.97
- Positive: Return on assets ratio (scaled to [-100,100]) of 33.91 > 6.06
- Negative: Industry earnings per price (median), % of -15.99 <= 0
Short-term BCRX quotes
Long-term BCRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $331.41MM | $450.71MM | $874.84MM |
| Operating Expenses | $435.12MM | $453.25MM | $533.85MM |
| Operating Income | $-103.71MM | $-2.54MM | $340.99MM |
| Non-Operating Income | $-122.52MM | $-84.41MM | $-73.60MM |
| Interest Expense | $108.24MM | $98.52MM | $78.87MM |
| R&D Expense | $216.57MM | $174.64MM | $166.13MM |
| Income(Loss) | $-226.23MM | $-86.95MM | $267.39MM |
| Taxes | $0.31MM | $1.93MM | $3.53MM |
| Net Income(Loss)* | $-226.54MM | $-88.88MM | $263.86MM |
| Stockholders Equity | $-455.53MM | $-475.93MM | $-119.15MM |
| Assets | $516.96MM | $490.42MM | $514.16MM |
| Operating Cash Flow | $-95.14MM | $-52.02MM | $347.37MM |
| Capital expenditure | $2.17MM | $1.12MM | $2.47MM |
| Investing Cash Flow | $-131.50MM | $52.59MM | $-13.69MM |
| Financing Cash Flow | $32.48MM | $-5.76MM | $-349.93MM |
| Earnings Per Share** | $-1.18 | $-0.43 | $1.26 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.